Skip to Main Content

Paper Details

One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.
19
2018
CVEs, CZP, Patients, RA, SIEs, TNF, TNFi, U, a, adalimumab, cardiovascular events, certolizumab pegol, etanercept, golimumab, infliximab, malignancies, patients, rheumatoid arthritis, tumor necrosis factor
Author NameAffiliation
Jeffrey D GreenbergNew York University School of Medicine
Joel M KremerAlbany Medical College
  • 1 - 2

Datasets

Release 1.2